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Summary
 
N
 
-formylpeptides derive from bacterial and mitochondrial proteins, and bind to specific recep-
tors on mammalian phagocytes. Since binding induces chemotaxis and activation of phagocytes
in vitro, it has been postulated that 
 
N
 
-formylpeptide receptor signaling in vivo may be impor-
tant in antimicrobial host defense, although direct proof has been lacking. Here we test this hy-
pothesis in mice lacking the high affinity 
 
N
 
-formylpeptide receptor (FPR), created by targeted
gene disruption. FPR
 
2/2
 
 mice developed normally, but had increased susceptibility to chal-
lenge with 
 
Listeria monocytogenes
 
, as measured by increased mortality compared with wild-type
littermates. FPR
 
2/2
 
 mice also had increased bacterial load in spleen and liver 2 d after infection,
which is before development of a specific cellular immune response, suggesting a defect in in-
nate immunity. Consistent with this, neutrophil chemotaxis in vitro and neutrophil mobiliza-
tion into peripheral blood in vivo in response to the prototype 
 
N
 
-formylpeptide fMLF
(formyl-methionyl-leucyl-phenylalanine) were both absent in FPR
 
2/2
 
 mice. These results in-
dicate that FPR functions in antibacterial host defense in vivo.
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P
 
erhaps the most widely used probes for studying mech-
anisms of leukocyte chemotaxis are the 
 
N
 
-formylpep-
tides, particularly the prototype formyl-methionyl-leucyl-
 
phenylalanine (fMLF).
 
1
 
 However, after over 20 years of
research, their biological significance is still unknown (for
review see reference 1). At one extreme, they could simply
mimic in vitro an endogenous leukocyte chemoattractant
not yet described, and have no biological role themselves.
At the other, they may be very important in antibacterial
host defense. The latter view has substantial indirect sup-
port because 
 
N
 
-formylpeptides are products of bacterial
proteins (2–4), and because phagocytes are critical effectors
of antibacterial host defense.
The 
 
N
 
-formylpeptide signaling pathway has been stud-
ied in detail in vitro. Specific phagocyte receptors have
been characterized biochemically, and two human genes,
designated 
 
FPR1
 
 and 
 
FPRL1
 
, that encode specific 
 
N
 
-for-
mylpeptide receptor subtypes, have been cloned (5–9).
Both are members of the 7-transmembrane domain recep-
tor superfamily, and both couple to pertussis toxin–sensi-
tive G proteins (10). They each have 69% deduced amino
acid sequence identity, and are commonly referred to as
FPR (formyl peptide receptor) and the FPRL1 (FPR-like
1) receptor, respectively. Both are expressed in human
neutrophils and monocytes (11), both bind fMLF (5, 8),
and, when activated, both induce calcium mobilization in
transfected cells (6, 8, 11). However, there are several ma-
jor differences: FPR binds fMLF with an 
 
z
 
1,000-fold
higher affinity than FPRL1 (8); FPR, but not FPRL1, has
been shown to be a chemotactic receptor (12); and FPRL1,
but not FPR, has been shown to be a functional lipoxin A4
receptor (13). One other related human gene, named
 
FPRL2
 
, has been identified by cross-hybridization, but the
function of the putative receptor is undefined (9, 11). All
three genes are clustered on chromosome 19q13.3 (14).
In mice, an orthologue of 
 
FPR1
 
 and five structurally re-
lated genes have been identified by cross-hybridization
with human FPR and FPRL1 probes, indicating that the
FPR gene cluster has undergone differential lineage-spe-
cific expansion in mammals (15–17). This has created prob-
lems in defining orthologous genes in the two species. The
mouse orthologue of human 
 
FPR1
 
 is clearly encoded by
the mouse gene 
 
Fpr1
 
. The encoded receptor is 77% identi-
cal in amino acid sequence to human FPR and responds to
fMLF in calcium flux assays, although the EC
 
50
 
 is 
 
z
 
100-
 
1
 
Abbreviations used in this paper:
 
 fMLF, formyl-methionyl-leucyl-phenylal-
anine; FPR, high affinity 
 
N
 
-formylpeptide receptor; FPRL1, low affinity
 
N
 
-formylpeptide receptor or lipoxin A4 receptor; MIP, macrophage in-
flammatory protein; ORF, open reading frame; TP neutrophils, thiogly-
collate-elicited peritoneal neutrophils. 
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fold higher than for human FPR under comparable condi-
tions (15). Like 
 
FPRL1
 
, one of the related mouse genes,
designated 
 
Fpr-rs1
 
, encodes a lipoxin A4 receptor. How-
ever, neither this nor the other four related genes has been
shown to encode a receptor specific for 
 
N
 
-formylpeptides
or other chemoattractant ligands (17).
Although several antagonists of fMLF have been re-
ported (18), they have not been developed extensively as
pharmacologic tools for defining 
 
N
 
-formylpeptide biology.
We have taken an alternative genetic approach, through
analysis of mice lacking FPR, by targeted disruption of 
 
Fpr1
 
.
 
Materials and Methods
 
Generation of FPR
 
2/2
 
 Mice.
 
Cloning of the FPR gene (
 
Fpr1
 
)
from a B6/CBA mouse genomic library has been described pre-
viously (15). A 7.8-kb XbaI fragment of genomic clone X was
cloned into Bluescript (Stratagene). To facilitate creation of a tar-
geting construct, three restriction enzyme sites were created in
this fragment: a KpnI site 700 bp upstream of the start codon of
the open reading frame (ORF), and BamHI and XhoI sites 300
and 450 bp downstream of the start codon, respectively. The
150-bp BamHI/XhoI ORF fragment, which encodes the puta-
tive first extracellular loop to the fourth transmembrane domain
of FPR, was replaced by a 1.1-kb neomycin resistance cassette
(
 
neo
 
r
 
) inserted in the opposite orientation. A 6.9-kb fragment of
the resulting construct was excised by digestion of a NotI site in
the polylinker at the 3
 
9
 
 end and the artificial KpnI site at the 5
 
9
 
end, and subcloned between NotI and KpnI sites of the plasmid
pPNT (19), which contains the Herpes simplex virus thymidine
kinase (HSV-
 
tk
 
) gene. The resulting construct contained 1 and
4.8 kb of FPR sequence 5
 
9
 
 and 3
 
9
 
 from the 
 
neo
 
r
 
 gene, respec-
tively. The construct was linearized by digestion with XbaI, and
25 
 
m
 
g DNA was electroporated into 10
 
7
 
 cells from the embry-
onic stem cell line designated R1.211 clones resistant to G418
(350 
 
m
 
g/ml) and gancyclovir (2 
 
m
 
M) were selected and expanded
on feeder cell layers in 24-well plates. Homologous recombinants
were identified by Southern blot hybridization of genomic DNA
digested with XbaI with a 1-kb probe located outside of the con-
struct. Five chimeric mice were produced by microinjection into
C57Bl/6 blastocysts according to standard methods (20). Chi-
meric mice were mated with wild-type C57Bl/6 mice to pro-
duce heterozygous (
 
1
 
/
 
2
 
) mice. Litter mates from the mating of
heterozygous mice were then analyzed. This work was done un-
der a protocol approved by the Animal Care and Use Committee
of the National Institute of Allergy and Infectious Diseases.
 
Isolation of Mouse Leukocytes.
 
Total leukocytes (80–85% mono-
nuclear cells and 15–20% neutrophils) were isolated from citrated
peripheral blood obtained from mouse tails; erythrocytes were
lysed in ACK lysis buffer. To obtain enriched populations of
neutrophils and macrophages, the peritoneal cavity was washed
with PBS 3 and 72 h, respectively, after peritoneal injection with
2 ml (for neutrophils) or 1 ml (for macrophages) of thioglycollate.
The purity of both populations was 
 
.
 
90% as assessed by light mi-
croscopy of Diff-quick–stained (Sigma Chemical Co.) cytospin
preparations.
 
Analysis of mRNA Expression.
 
Total RNA was prepared from
peritoneal exudate neutrophils with RNA STAT-60 kit (Tel-
Test, Inc.) according to the manufacturer’s instructions. The
cDNA was synthesized with cDNA Cycle kit (Invitrogen). Wild-
type and mutated FPR mRNA was screened by PCR using
primers FPR310 (5
 
9
 
-ATGTTCTAGGAGTCTACAAGATGG,
 
a sense oligonucleotide located 20 bp before the start codon),
AFPR660 (5
 
9
 
-ATATATGAATTTGCACATGAACCA, an an-
tisense oligonucleotide located in the deleted part of the ORF
in the targeting construct), and SNEO2 (5
 
9
 
-CGCTCCCGAT-
TCGCAGCGCATCGC, a sense oligonucleotide of the 
 
neo
 
gene). Primers FPR310 and AFPR660 amplify 350 bp of wild-
type cDNA, and primers FPR310 and SNEO2 amplify 430 bp of
mutated cDNA. The PCR conditions were 94
 
8
 
C for 5 min, fol-
lowed by 30 cycles of 94
 
8
 
C for 30 s, 60
 
8
 
C for 30 s, and 70
 
8
 
C for
30 s, with a final extension at 72
 
8
 
C for 10 min.
 
[Ca
 
2
 
1
 
]
 
i
 
 Measurements.
 
Cells (10
 
7
 
/ml) were loaded with FURA-2
(Molecular Probes) as previously described (21). 2 
 
3 
 
10
 
6
 
 cells in 2
ml HBSS were placed in a continuously stirred cuvette at 37
 
8
 
C in
a fluorimeter (Photon Technology Inc.). The data are presented
as the relative ratio of fluorescence excited alternately at 340 and
380 nm every 0.5 s, and monitored at 510 nm, in response to
fMLF (Sigma Chemical Co.) or recombinant mouse macrophage
inflammatory protein (MIP)-1
 
a
 
 (Peprotech).
 
Chemotaxis.
 
Chemotaxis was analyzed using polyvinylpyr-
rolidone-free polycarbonate membranes with 3-
 
m
 
m pores in 48-
well chambers (NeuroProbe). fMLF in HBSS was placed in the
lower chamber, and 50 
 
m
 
l of thioglycollate-elicited peritoneal
neutrophils suspended in HBSS (1.5 
 
3 
 
10
 
6
 
/ml) were placed in
the upper chamber. After incubation for 45 min at 37
 
8
 
C, the
membrane was removed, rinsed with PBS, fixed, and stained
with Diff-Quick. Cells were counted in five randomly selected
fields at 1,000-fold magnification.
 
Neutrophil Mobilization to Peripheral Blood.
 
Mice were injected
subcutaneously with 200 
 
m
 
l of 2 
 
m
 
M fMLF. Complete peripheral
blood leukocyte counts and differentials were determined for tail
vein collections taken before injection and 1.5 h after injection.
 
Challenge with Listeria monocytogenes.
 
The experimental pro-
cedure has been described previously (22). In brief, log-phase
culture of 
 
L
 
.
 
 monocytogenes
 
 strain EGD was grown in brain–heart
infusion broth (Difco Labs.), aliquoted in 1-ml volumes, and
stored at 
 
2
 
70
 
8
 
C. For each experiment, a vial of bacteria was
thawed and diluted in PBS. In initial experiments, the approxi-
mate intravenous LD
 
50
 
 in first and second generation B6/129
heterozygote mice for 
 
L
 
.
 
 monocytogenes
 
 was determined to be 2 
 
3
 
10
 
4
 
 CFU. Then, 6–8-wk-old mice were infected intravenously
with 0.1 ml of a suspension containing the LD
 
50
 
. For the bacterial
burden assay, mice were killed by cervical dislocation 48 h after
infection. Liver and spleen were removed and homogenized sep-
arately in distilled water, and numbers of viable 
 
L
 
.
 
 monocytogenes
 
were determined by plating serial dilutions of organ homogenates
on brain–heart infusion agar.
 
Results and Discussion
 
Development of Mice Lacking FPR.
 
To inactivate FPR,
we replaced a 150-bp ORF fragment of 
 
Fpr1 
 
with a neo-
mycin resistance cassette (
 
neo
 
r
 
) by homologous recombina-
tion in 129/Sv embryonic stem cells (Fig. 1 a). The deleted
region is from the first extracellular loop to the fourth
transmembrane segment predicted from the FPR sequence
(codons 101–150). The mutated and wild-type alleles were
distinguished by an XbaI restriction fragment length poly-
morphism, 8.5 versus 7.8 kb respectively, of genomic
DNA by Southern hybridization (Fig. 1 b). Consistent
with this, mutant FPR mRNA was detected in neutrophils
from 
 
1/2
 
 and 
 
2/2
 
, but not 
 
1/1
 
, mice, whereas normal 
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FPR mRNA was detected in neutrophils from 
 
1/2
 
 and
 
1/1
 
, but not 
 
2/2
 
, mice (Fig. 1 c).
The genotypic frequencies for 264 total progeny of eight
 
1/2
 
 mating pairs were: 24.4% 
 
1/1
 
, 49.6% 
 
1/2
 
, and
26.0% 
 
2/2
 
, which is not significantly different from Men-
delian expectation for an autosomal gene. FPR
 
2/2
 
 mice
were viable and fertile, and exhibited normal growth, de-
velopment, anatomy, and behavior compared with 1/1
littermates. In particular, no defects in the complete blood
count or differential white blood cell count were detected.
These mice have been observed for .17 mo, and have not
exhibited defects in hemostasis or healing of tail wounds, or
increased susceptibility to spontaneous infection when de-
rived in a specific pathogen-free environment. Thus either
FPR is not involved in these processes or it functions re-
dundantly with other factors, or else, under unstressed con-
ditions, its function is compensated by other factors in mu-
tant mice.
Role of FPR in Neutrophil Function. We first used the
knockout mice to test whether FPR mediates fMLF signal-
ing in primary leukocytes. First, we observed that the nor-
mal fMLF-induced calcium flux in thioglycollate-elicited
peritoneal (TP) neutrophils (Fig. 2 a) and PBMCs (data not
shown) from 1/1 mice was absent in cells from 2/2
mice. As a positive control, a robust response to the CC
chemokine MIP-1a was detected in the same cell types
from both 1/1 and 2/2 mice, consistent with previous
observations (23). TP neutrophils from FPR2/2 mice also
failed to chemotax in response to fMLF (100 nM–1 mM) in
vitro, whereas neutrophils from 1/1 mice exhibited a typ-
ical bell-shaped dose–response curve (Fig. 2 b). Similar re-
sults were obtained from TP macrophages, but the re-
sponse of 1/1 macrophages to fMLF was much lower than
the response of 1/1 neutrophils (data not shown). These
in vitro results indicate that FPR mediates mouse neutro-
phil chemotactic and calcium flux responses to fMLF,
which has not been shown previously, and verify gene in-
activation at the functional level.
We next tested the effects of fMLF in vivo in 1/1 and
2/2 mice. We found that subcutaneous injection of 1/1
mice with fMLF specifically induced a 70% increase in pe-
ripheral blood neutrophil concentrations when measured
90 min after injection (Fig. 2 c). The response was absent
in 2/2 mice, indicating that FPR is involved. The CC
chemokine MIP-1a is also able to induce this response,
through the receptor CCR1 (23). We also injected 1, 10,
and 100 nmoles of fMLF intraperitoneally, but did not ob-
serve local accumulation of leukocytes in either 1/1 or 2/2
mice when the peritoneal cavity was washed 4 h after in-
jection. Presumably, the peptide is scavenged or degraded
by factors present at this site. In contrast, intraperitoneal
injection with thioglycollate, a nonspecific inflammatory
stimulus, induced peritoneal exudation, with neutrophil
Figure 1. Genetic inactivation of mouse FPR. (a) Mutagenesis strategy.
Maps of the wild-type and mutant alleles are shown above and below the
map of the targeting construct, respectively, and corresponding sites are
connected by broken lines. The neomycin resistance gene (neor) replaced
150 bp of the FPR ORF and was used to select for targeted events. The
Herpes simplex virus thymidine kinase gene (HSV-tk) was used for coun-
terselection of nontargeted events. Horizontal bars, ORFs of the indi-
cated genes; arrows, sense orientation of the indicated ORF; X, XhoI; B,
BamHI; K, KpnI. (b) Genotypic analysis of tail DNA derived from prog-
eny of heterozygous crosses. The mutated allele (8.5-kb XbaI fragment) is
distinguished from the wild-type allele (7.8-kb XbaI fragment) using a
1-kb probe, whose location is given in panel a. (c) Reverse transcription
PCR analysis of total RNA from TP neutrophils from mice with the
FPR genotype indicated at the top of each lane. Mutated mRNA (430-
bp band) is distinguished from the wild-type mRNA (350-bp band) by
reverse transcription PCR with the primers indicated in the text.
Figure 2. Loss of FPR func-
tion in neutrophils from FPR2/2
mice. (a) Calcium flux re-
sponse. [Ca21]i was monitored
in real time in FURA-2–loaded
peritoneal neutrophils stimu-
lated with 1 mM fMLF and 100
nM MIP-1a. Each tracing repre-
sents analysis of 3 3 106 cells
from a single mouse with the
FPR genotype indicated at the
top (1/1, wild-type mice; 2/2,
knockout mice). Agonists were
added at the times indicated by the arrows. Results are from a single experiment representative of at least four separate experiments. (b) Neutrophil
chemotaxis. Results are the mean 6 SEM of triplicate determinations in a single experiment using peritoneal neutrophils and fMLF in vitro and are rep-
resentative of three separate experiments. There was no difference in MIP-1a–induced chemotaxis between neutrophils from FPR2/2 and from FPR1/1
mice (data not shown). (c) Neutrophil mobilization to peripheral blood. Each pair of bars represents the peripheral blood neutrophil concentration for a
single mouse before and 90 min after subcutaneous injection with 200 ml of 2 mM fMLF. Results are from a single experiment representative of three
separate experiments.660 N-formylpeptide Receptor–deficient Mice
and macrophage predominance at 4 and 72 h, respectively,
consistent with previous reports (23). However, no signifi-
cant difference was observed for this response between
FPR2/2 and FPR1/1 mice. Reduced leukocyte mobiliza-
tion in response to thioglycollate has been reported in sev-
eral chemokine receptor knockout mice (24–28) and in
C5a receptor knockout mice (29), all of which bind endog-
enous chemoattractants. Thus, thioglycollate challenge in
FPR knockout mice does not reveal evidence for the widely
held speculation that an endogenous ligand for FPR exists.
Increased Susceptibility of FPR2/2 Mice to Challenge with L.
monocytogenes. To test the role of FPR in host defense, we
compared the susceptibility of FPR2/2 and FPR1/1 mice
to infection with L. monocytogenes. This organism was cho-
sen because it produces an acute infection in mice with
well-characterized immunopathogenesis (30), involving both
innate and acquired arms of the immune system, and be-
cause, like other bacteria, it produces N-formylpeptides (31).
It is not known whether Listeria-derived N-formylpeptides
are released in vivo in amounts required to activate FPR;
however, this is also unknown for other bacteria. FPR2/2
mice exhibited a markedly higher rate and extent of mor-
tality compared with FPR1/1 littermates (Fig. 3 a). 73% of
FPR2/2 mice injected with 2 3 104 CFU died by day 4 in
contrast to only 6% in FPR1/1 mice. Only 6% of FPR2/2
mice survived beyond 6 d, whereas 50% of FPR1/1 mice
remained healthy. The survival curve of 1/2 mice fell
between those of 2/2 and 1/1 mice, suggesting a gene
dosage effect for this phenotype. Consistent with this, we
observed intermediate responsiveness of neutrophils from
1/2 mice versus 2/2 and 1/1 mice to fMLF in the
calcium flux assay (data not shown).
Early mortality suggests a defect in innate immunity. To
test this further, we infected mice with 2 3 104 CFU and
measured bacterial burden 2 d later, a time when nonspe-
cific immune responses control infection (30). Consistent
with a defect in innate immunity, FPR2/2 mice showed
32- and 45-fold more bacteria in spleen and liver, respec-
tively, at this time, relative to 1/1 control mice (Fig. 3 b).
Although our results show that FPR deficiency causes
increased susceptibility to Listeria infection, they do not
clearly identify its mechanism of action. The histopatho-
logic appearance of the liver and spleen was indistinguish-
able in infected FPR1/1 and FPR2/2 mice killed on days 1,
2, and 3 after infection, and in infected animals with dis-
cordant genotypes that were allowed to die naturally. In
both cases, neutrophilic abscesses were observed, suggest-
ing that FPR deficiency does not affect normal neutrophil
trafficking to these organs in this model. Additional work
will be needed to identify the precise mechanism of action
of FPR in host defense in this model.
It has been demonstrated previously that, as in FPR-defi-
cient mice, neutrophil-depleted mice rapidly succumb to
overwhelming listeriosis after experimental challenge, with
marked increases in bacterial burden in both liver and
spleen (32, 33). Disruption of other genes that regulate phago-
cyte  function, including the genes encoding gp91phox (a
component of the phagocyte NADPH oxidase; reference
34), the IFN-g receptor (35), and the chemokine receptors
CCR2 (24) and CCR5 (25), has also been linked to in-
creased susceptibility to Listeria. Since not all FPR2/2 mice
died from Listeria challenge in our experiments, these and
other genes may compensate, at least partially, when FPR
is absent.
In summary, we have found that FPR2/2 mice have no
obvious developmental defects and do not develop sponta-
neous infection when derived in specific pathogen-free
conditions. This suggest that, under these conditions, FPR
is dispensable. However, when challenged with L. monocy-
togenes, FPR-deficient mice have accelerated mortality and
increased bacterial burden in liver and spleen early after in-
fection, which suggests a role for FPR in host defense, spe-
cifically through regulation of innate immunity. This is
consistent with expression of FPR on phagocytes. Addi-
tional work will be needed to establish whether FPR is a
host defense factor versus other types of microorganisms,
and a factor in inflammation induced by noninfectious
agents, as well as to establish whether its mechanism of ac-
tion in listeriosis involves binding of N-formylpeptides and
trafficking of phagocytes.
We thank Karen Elkins for Listeria strains, helpful advice, and comments on the manuscript, and Heiner
Westphal for helpful advice.
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Figure 3. Anti-listerial host
defense in mice lacking FPR. (a)
Accelerated lethality in FPR2/2
mice challenged with L. monocy-
togenes. Mice were injected with
2 3 104 CFU in the tail vein.
Results are from a single experi-
ment with 2/2 and 1/1 sex-
matched littermates (n 5 15 in
each group), and are representa-
tive of three separate experi-
ments with a consistent pattern.
P 5 0.003 for 1/1 versus 2/2;
P 5 0.038 for 1/2 versus 2/2
(log-rank test). (b) Listeria clear-
ance. Under the same conditions
as in panel a, the bacterial burden
from whole spleen and liver was
determined 2 d after infection.
The mean values are indicated
as solid bars. 1/1, wild-type
mice;  2/2, knockout mice.661 Gao et al.
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